Rune Labs has hired a new CEO who previously held a senior position at Tempus. The company also announced plans to expand its operations into the field of Alzheimer's disease. The aim of this expansion is to use its existing technological and data capacities in a new therapeutic area. The article states that this is a strategic step in the company's development. The new leadership is to help accelerate the growth and expansion of Rune Labs products. The text does not include specific statistics or results of clinical studies. Detailed clinical findings related to Alzheimer's disease are also not described. The article focuses mainly on the personnel change in management and the direction of the company in a new area.